Search: onr:"swepub:oai:gup.ub.gu.se/52248" >
Effect of candesart...
Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
-
O'Meara, E. (author)
-
Solomon, S. (author)
-
McMurray, J. (author)
-
show more...
-
Pfeffer, M. (author)
-
Yusuf, S. (author)
-
Michelson, E. (author)
-
Granger, C. (author)
-
Olofsson, B. (author)
-
Young, J. B. (author)
-
- Swedberg, Karl, 1944 (author)
- Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute
-
show less...
-
(creator_code:org_t)
- Oxford University Press (OUP), 2004
- 2004
- English.
-
In: European heart journal. - : Oxford University Press (OUP). - 0195-668X. ; 25:21, s. 1920-6
- Related links:
-
https://academic.oup...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- AIMS: To evaluate the effect of the angiotensin receptor blocker candesartan on New York Heart Association (NYHA) functional class in a broad spectrum of patients with chronic heart failure (CHF). METHODS AND RESULTS: Patients in the CHARM Programme with symptomatic CHF were randomized to placebo (n=3796) or candesartan (n=3803) and followed for a median of 38 months. NYHA class was assessed at baseline, at two weekly intervals during dose titration and 4 monthly thereafter. Patients were classified as "better", "unchanged" or "worse" at the end of the study compared to baseline. Both a simple "last visit carried forward" (LVCF) analysis and "worst rank carried forward" (WRCF) analysis (where patients who died were allocated NYHA class V) were used. In the LVCF analysis, compared to placebo, more candesartan patients improved (35.4% versus 32.5%) and fewer worsened (9.0% versus 10.3%) in NYHA class (p=0.003). The WRCF analysis also showed a better overall change in NYHA class with candesartan compared to placebo. There was no heterogeneity in the response to candesartan between the CHARM component trials. CONCLUSIONS: Candesartan improves NYHA functional class to a similar extent to other proven treatments for CHF when added to these other treatments.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- Adult
- Aged
- Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
- Benzimidazoles/*therapeutic use
- Female
- Heart Failure
- Congestive/*drug therapy/mortality
- Humans
- Male
- Middle Aged
- Tetrazoles/*therapeutic use
- Treatment Outcome
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
O'Meara, E.
-
Solomon, S.
-
McMurray, J.
-
Pfeffer, M.
-
Yusuf, S.
-
Michelson, E.
-
show more...
-
Granger, C.
-
Olofsson, B.
-
Young, J. B.
-
Swedberg, Karl, ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
European heart j ...
- By the university
-
University of Gothenburg